自身免疫有助于黑色素瘤患者存活。 - Suppr

Suppr

超能文献

Autoimmunity aids survival in melanoma.

作者信息

Senior Kathryn

出版信息

Lancet Oncol. 2006 Apr;7(4):289. doi: 10.1016/s1470-2045(06)70641-6.

DOI:10.1016/s1470-2045(06)70641-6

PMID:16598882

Abstract

摘要

相似文献

Autoimmunity aids survival in melanoma.

Lancet Oncol. 2006 Apr;7(4):289. doi: 10.1016/s1470-2045(06)70641-6.

Autoimmunity as a prognostic factor in melanoma patients treated with adjuvant low-dose interferon alpha.

Int J Cancer. 2007 Dec 1;121(11):2562-6. doi: 10.1002/ijc.22951.

Autoimmunity and immunotherapy for cancer.

N Engl J Med. 2006 Feb 16;354(7):758-60. doi: 10.1056/NEJMe058307.

[After removal of a malignant melanoma. Enhancing the immune system!].

MMW Fortschr Med. 1999 Nov 4;141(44):66.

Adjuvant use of interferon alpha 2b is not justified in patients with stage IIb/III melanoma.

Nat Clin Pract Oncol. 2008 Jan;5(1):4-5. doi: 10.1038/ncponc1007. Epub 2007 Nov 27.

Prognostic significance of autoimmunity during treatment of melanoma with interferon.

N Engl J Med. 2006 Feb 16;354(7):709-18. doi: 10.1056/NEJMoa053007.

High-dose adjuvant interferon therapy for melanoma.

Dermatol Nurs. 1998 Oct;10(5):334-6.

Adjuvant interferon therapy for melanoma.

J Clin Oncol. 2005 Apr 1;23(10):2431; author reply 2431-2. doi: 10.1200/JCO.2005.99.260.

[Autoimmunity induced by low doses of interferon in melanoma stage I].

Ann Dermatol Venereol. 2006 Jun-Jul;133(6-7):543-8. doi: 10.1016/s0151-9638(06)70959-0.

Adjuvant interferon for melanoma.

Ann Oncol. 2002 Aug;13(8):1319-20; author reply 1320. doi: 10.1093/oxfordjournals.annonc.a000325.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Autoimmunity aids survival in melanoma.

Lancet Oncol. 2006 Apr;7(4):289. doi: 10.1016/s1470-2045(06)70641-6.

Autoimmunity as a prognostic factor in melanoma patients treated with adjuvant low-dose interferon alpha.

Int J Cancer. 2007 Dec 1;121(11):2562-6. doi: 10.1002/ijc.22951.

Autoimmunity and immunotherapy for cancer.

N Engl J Med. 2006 Feb 16;354(7):758-60. doi: 10.1056/NEJMe058307.

[After removal of a malignant melanoma. Enhancing the immune system!].

MMW Fortschr Med. 1999 Nov 4;141(44):66.

Adjuvant use of interferon alpha 2b is not justified in patients with stage IIb/III melanoma.

Nat Clin Pract Oncol. 2008 Jan;5(1):4-5. doi: 10.1038/ncponc1007. Epub 2007 Nov 27.

Prognostic significance of autoimmunity during treatment of melanoma with interferon.

N Engl J Med. 2006 Feb 16;354(7):709-18. doi: 10.1056/NEJMoa053007.

High-dose adjuvant interferon therapy for melanoma.

Dermatol Nurs. 1998 Oct;10(5):334-6.

Adjuvant interferon therapy for melanoma.

J Clin Oncol. 2005 Apr 1;23(10):2431; author reply 2431-2. doi: 10.1200/JCO.2005.99.260.

[Autoimmunity induced by low doses of interferon in melanoma stage I].

Ann Dermatol Venereol. 2006 Jun-Jul;133(6-7):543-8. doi: 10.1016/s0151-9638(06)70959-0.

Adjuvant interferon for melanoma.

Ann Oncol. 2002 Aug;13(8):1319-20; author reply 1320. doi: 10.1093/oxfordjournals.annonc.a000325.